Reaction
Medical Device Implantation reporting signals
As of the last recalculation, Medical Device Implantation appears in 1,498 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is UPADACITINIB (PRR 28.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Upadacitinib | 150 | 28.3 | 28.4 |
| Risankizumab-Rzaa | 146 | 27.4 | 27.4 |
| Pancrelipase | 38 | 14.0 | 14.0 |
| Ibrutinib | 61 | 10.9 | 10.9 |
| Carboxymethylcellulose Sodium | 6 | 8.9 | 8.9 |
| Brivaracetam | 5 | 7.7 | 7.8 |
| Vibegron | 4 | 6.9 | 7.0 |
| Linaclotide | 12 | 6.3 | 6.3 |
| Carbidopa And Levodopa | 21 | 6.2 | 6.2 |
| Venetoclax | 25 | 5.7 | 5.7 |
| Romosozumab-Aqqg | 4 | 4.1 | 4.1 |
| Droxidopa | 6 | 3.9 | 3.9 |
| Fremanezumab-Vfrm | 3 | 3.6 | 3.6 |
| Palivizumab | 3 | 2.7 | 2.7 |
| Evolocumab | 31 | 2.7 | 2.7 |